FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. A group of inventions is described, including a single-stranded variable fragment (scFv) specifically binding to the human B-cell maturation antigen (human BCMA), a chimeric antigen receptor (CAR) to human BCMA, a nucleic acid molecule encoding the above chimeric antigen receptor, an expression vector, a CAR-T cell for destroying BCMA-positive cancer cells, a method for destroying BCMA-positive cancer cells, a method for obtaining a CAR-T cell to human BCMA. In one embodiment, a single-stranded variable fragment contains a variable region (VH) of a heavy chain having the amino acid sequence SEQ ID NO: 3; and a variable region (VL) of a light chain having the amino acid sequence SEQ ID NO: 5.
EFFECT: antibodies are proposed, binding BCMA cells.
14 cl, 11 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
